Table 1. Characteristics of Population-Based Cases and Controls By Hair Loss Pattern at Age 30 Years and at One Year Before Reference Date.
| Cases | Controls | |||||
|---|---|---|---|---|---|---|
| No Hair Loss N (%) | Hair Loss at Age 30 N (%) | Hair Loss at Referent Age Only N (%) | No Hair Loss N (%) | Hair Loss at Age 30 N (%) | Hair Loss at Referent Age Only N (%) | |
| Subjects | 391 | 198 | 410 | 337 | 237 | 368 |
| Age at Reference Date (years) | ||||||
| 40 - 49 | 45 (11.5) | 22 (11.1) | 26 (6.3) | 44 (13.1) | 30 (12.7) | 22 (6.0) |
| 50 – 54 | 51 (13.0) | 27 (13.6) | 30 (7.3) | 49 (14.5) | 22 (9.3) | 42 (11.4) |
| 55 – 59 | 81 (20.7) | 39 (19.7) | 64 (15.6) | 80 (23.7) | 45 (19.0) | 49 (13.3) |
| 60 – 64 | 82 (21.0) | 42 (21.2) | 93 (22.7) | 68 (20.2) | 50 (21.1) | 69 (18.8) |
| 65 – 69 | 75 (19.2) | 33 (16.7) | 101 (24.6) | 58 (17.2) | 48 (20.3) | 96 (26.1) |
| 70 – 74 | 57 (15.9) | 35 (17.7) | 96 (23.4) | 38 (11.3) | 42 (17.7) | 90 (24.5) |
| Race | ||||||
| Caucasian | 328 (83.9) | 174 (87.9) | 339 (82.7) | 292 (86.7) | 221 (93.3) | 331 (90.0) |
| African-American | 63 (16.1) | 24 (12.1) | 71 (17.3) | 45 (13.4) | 16 (6.8) | 37 (10.1) |
| Family History of Prostate Cancer | ||||||
| No | 313 (80.1) | 149 (75.3) | 311 (75.9) | 297 (88.1) | 207 (87.3) | 329 (89.4) |
| Yes | 78 (20.0) | 49 (24.8) | 99 (24.2) | 40 (11.9) | 30 (12.7) | 39 (10.6) |
| PSA Screening History* | ||||||
| No PSA performed | 99 (25.3) | 45 (22.7) | 75 (18.3) | 102 (30.3) | 63 (26.6) | 75 (20.4) |
| 1 – 2 PSAs | 72 (18.4) | 40 (20.2) | 60 (14.6) | 59 (17.5) | 45 (19.0) | 64 (17.4) |
| ≥ 3 PSAs | 199 (50.9) | 101 (51.0) | 245 (60.0) | 113 (33.5) | 95 (38.8) | 175 (47.6) |
| Unknown | 21 (5.4) | 12 (6.1) | 30 (7.3) | 63 (18.7) | 37 (15.6) | 54 (14.7) |
| PSA | ||||||
| < 4.0 ng/mL | 49 (13.5) | 28 (14.5) | 56 (14.7) | 265 (94.0) | 186 (92.5) | 270 (88.8) |
| 4.0 – 9.9 ng/mL | 231 (63.5) | 127 (65.8) | 233 (61.3) | 15 (5.3) | 13 (6.5) | 27 (8.9) |
| > 10 ng/mL | 84 (23.1) | 38 (19.7) | 91 (24.0) | 2 (0.7) | 2 (1.0) | 7 (2.3) |
| BMI | ||||||
| Normal (< 25) | 108 (27.6) | 61 (30.8) | 118 (28.8) | 103 (30.6) | 59 (24.9) | 97 (26.4) |
| Overweight (25 – 29.9) | 197 (50.4) | 93 (47.0) | 201 (49.0) | 155 (46.0) | 110 (46.4) | 179 (48.6) |
| Obese (≥ 30) | 86 (22.0) | 44 (22.2) | 91 (22.2) | 79 (23.4) | 68 (28.7) | 92 (25.0) |
| Propecia Use | ||||||
| Never | 388 (99.2) | 195 (98.5) | 404 (98.5) | 336 (99.7) | 235 (99.2) | 361 (98.1) |
| Ever | 3 (0.8) | 3 (1.5) | 6 (1.5) | 1 (0.3) | 2 (0.8) | 7 (1.9) |
| Proscar Use | ||||||
| Never | 383 (98.0) | 192 (98.5) | 400 (98.3) | 331 (98.5) | 236 (99.6) | 361 (98.1) |
| Ever | 8 (2.1) | 3 (1.5) | 7 (1.7) | 5 (1.5) | 1 (0.4) | 7 (1.9) |
*
Number of PSA screening tests done within the 5-years before reference date